EAM Investors’s Pacific Biosciences PACB Stock Holding History

EAM Investors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-85,761	Closed	-$1.14M	–	356
2023 Q2	$1.14M	Hold	85,761	–	–	0.21%	217
2023 Q1	$993K	Buy	+85,761	New	+$853K	0.2%	231
2020 Q4	–	Sell	-127,447	Closed	-$1.26M	–	365
2020 Q3	$1.26M	Buy	+127,447	New	+$734K	0.3%	149
2016 Q2	–	Sell	-110,172	Closed	-$936K	–	347
2016 Q1	$936K	Buy	110,172 +1,998	+2%	+$19.6K	0.15%	256
2015 Q4	$1.42M	Buy	+108,174	New	+$970K	0.19%	213
2013 Q4	–	Sell	-203,176	Closed	-$1.12M	–	343
2013 Q3	$1.12M	Buy	+203,176	New	+$705K	0.22%	215

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

EAM Investors's PACB Position: Q3 2023 in Review

EAM Investors sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 85,761 shares — an estimated $1.14M sold.

EAM Investors first reported a position in PACB in Q3 2013 and held it in 6 quarters. The position peaked at $1.42M in Q4 2015. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

EAM Investors reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 85,761 Pacific Biosciences shares in Q3 2023, an estimated $1.14M.
EAM Investors first reported a position in Pacific Biosciences in Q3 2013 and held it in 6 quarters.
EAM Investors's Pacific Biosciences position peaked at $1.42M in Q4 2015.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.